Abemaciclib (LY2835219) is an orally bioavailable, selective CDK4/6 inhibitor (IC50: 2 nM, 10 nM). It blocks retinoblastoma protein phosphorylation, inducing G1 phase arrest. Abemaciclib exhibits antitumor activity alone or in combination with other therapies in xenograft models. Reagent-grade; for laboratory research purposes only.
Usually ships within 24 hours.